Friedreich’s Ataxia

Friedreich's ataxia is usually caused by a long GAA repeat in both copies of the FXN gene. Using long-read genetic sequencing in 112 patients, researchers found that about one in five people carry a more complex version of this repeat, containing stretches of a different triplet, that standard testing often misses. Another 2% had a small FXN deletion. Overlooking these hidden patterns can lead to inaccurate genetic results for patients and carriers, so the team describes an improved workflow to detect them and genotype families correctly.

Friedreich's ataxia results from too little frataxin, a protein that mitochondria need to make energy. This review examines how frataxin shortage damages the nervous system, tracing the timing of changes across brain and spinal regions and why nerve cells are especially vulnerable. It highlights specific energy-related pathways, including fatty acid handling, ceramide production, and ketone metabolism, that may drive that vulnerability and could become targets for drugs or dietary approaches. The authors suggest interventions based on these metabolic features offer hope for easing the severity of the disease.

This review, written for child neurologists, summarizes what is known about Friedreich's ataxia now that the first treatment has arrived. It covers the disease's features, the underlying GAA repeat expansion in the FXN gene, everyday management, and the biology driving the illness. It gives particular attention to emerging therapies and to how the recent approval of omaveloxolone has raised the importance of recognizing FRDA early. It is a useful, up-to-date orientation for families and clinicians alike.

Tracking how Friedreich's ataxia changes over time in children is essential for testing new treatments. The FACHILD natural history study followed genetically confirmed patients aged 7 to 18 over three years, comparing walking tests, balance and dexterity measures, rating scales, and daily-living questionnaires to see which best capture progression. The one-minute walk stood out as sensitive in early to moderately affected children, performing comparably to an established neurological rating scale. Reliable, sensitive outcome measures like these make future clinical trials in young patients more feasible and informative.

In Friedreich's ataxia the FXN gene is switched off (epigenetically silenced) rather than deleted, so reawakening it could restore the missing frataxin. Researchers found that blocking two related enzymes, ROCK1 and ROCK2, reactivated the repressed FXN gene and raised frataxin levels in laboratory models. Because ROCK inhibitors already exist as drugs, this points to a potentially repurposable route to frataxin restoration. The work is preclinical, but it identifies a promising new therapeutic target for further study.

TRACK-FA is a large international study using standardized brain and spinal-cord MRI to find imaging markers of Friedreich's ataxia. In this cross-sectional analysis, the scans revealed consistent structural differences in people with FRDA compared with unaffected participants, in regions known to be affected by the disease. Reliable imaging markers matter because they can objectively track disease progression and show whether a treatment is helping, which could make future clinical trials shorter and more sensitive.

Friedreich ataxia (FRDA) is the most common inherited early-onset ataxia in people of European, Arab, and Indian descent, and this authoritative review takes stock of a fast-moving field. Over the past decade, scientists have clarified how the disease unfolds and launched multiple clinical trials, culminating in the approval of omaveloxolone, the first medicine specifically for FRDA. The authors review therapies now in the pipeline, lessons from trials that fell short, and a global research roadmap set by the new Friedreich's Ataxia Global Clinical Consortium spanning six continents.

Friedreich ataxia stems from too little frataxin, a small protein made inside mitochondria. This review explains the chain of damage: without enough frataxin, cells cannot properly build the iron-sulfur clusters that mitochondria need, so energy production falters, harmful reactive oxygen molecules accumulate, and iron builds up in certain tissues. These failures underlie the disease's wide reach, including loss of movement control, heart muscle disease, scoliosis, foot deformities, and diabetes. By linking one missing protein to problems across many organs, the review helps patients understand why FRDA affects so much of the body.

About 96% of people with Friedreich ataxia carry two expanded GAA repeats in the FXN gene, but roughly 4% have one expansion paired with a different kind of mutation (a missense, nonsense, or deletion change). This review examines what these rarer compound cases reveal. Some specific missense mutations produce unusual mixtures of milder and more severe features in the same person, hinting that frataxin does more than help build iron-sulfur clusters. Studying these exceptions sharpens understanding of the protein's full role and of how FRDA varies from person to person.

Even siblings who inherit Friedreich ataxia can differ in how and when it appears. This study analyzed 150 siblings from 70 families, comparing their age at onset with the length of their shorter GAA repeat (called GAA1) and a variant in the SIRT6 gene. Differences between siblings were generally modest, and GAA1 length explained only a small part of why onset ages varied; about a quarter of families differed in whether they developed heart muscle disease or scoliosis. The work underscores that repeat length matters but does not fully predict FRDA severity.

This engaging review, by a scientist central to the discovery, traces almost 30 years of Friedreich ataxia research since the FXN gene was identified in the early 1990s. It recounts how the disease was first described in the 1800s, mapped to chromosome 9 in 1988, and finally pinned to an expanded GAA repeat in FXN. That breakthrough enabled genetic testing and opened the doors to understanding frataxin's role, the cellular damage its shortage causes, and the search for biomarkers and treatments. A clear, accessible history for patients and families.

Diabetes is common in Friedreich ataxia, and this US study asked why, focusing on muscle. Because frataxin supports the energy-making machinery (mitochondria) in skeletal muscle, and muscle energy capacity influences how the body responds to insulin, researchers compared 11 adults who have FRDA but not yet diabetes with 24 controls. The FRDA group showed lower muscle mitochondrial capacity, less physical activity, more internal fat, and reduced insulin sensitivity, with higher insulin output compensating. The findings suggest muscle- or fat-focused strategies might one day help delay FRDA-related diabetes.

Measuring quality of life fairly matters when planning care and evaluating treatments. This German study, using 607 people from the EFACTS Friedreich ataxia cohort, tested whether a widely used generic questionnaire (the EQ-5D-3L) captures mobility well for patients who use wheelchairs or walking aids. It found the mobility question fit poorly: wheelchair users often left it blank, and walking-aid users almost all chose the same middle option, limiting its usefulness. The findings warn researchers that standard quality-of-life tools may misrepresent severely mobility-impaired FRDA patients and need careful interpretation.

Many experimental Friedreich ataxia therapies (gene therapy, protein replacement, gene editing, and drugs that boost FXN) all aim to restore the missing frataxin protein, so scientists need reliable tests to measure whether a treatment actually works. This study developed a cell-based potency assay using mouse cells engineered to make almost no frataxin, which show clear signs of the deficiency that adding frataxin reverses. The team validated these cells as a tool for testing new FRDA treatments, while cautioning that the cells can drift over time, an important quality-control lesson for drug developers.

Calcitriol, the active form of vitamin D, had raised frataxin levels in laboratory cell models of Friedreich ataxia, so researchers tested it in patients. Twenty people were enrolled and 15 completed a year of a low daily dose, with checks of neurological function and quality of life. Frataxin levels in blood platelets rose modestly, and the treatment was generally well tolerated with only minor early side effects, though no measurable neurological improvement was seen. As an early, small study, it shows the approach is safe and worth exploring further rather than proving benefit.

With only one approved medicine for Friedreich ataxia, this review surveys the full treatment landscape. It explains that the shortage of frataxin disrupts mitochondria and drives the disease's neurological, hormonal, orthopedic, and heart problems, and that omaveloxolone (Skyclarys), an Nrf2 activator, is currently the sole approved therapy, alongside various medicines used to ease symptoms. The authors summarize past trials, including ones that fell short, and argue that the most promising path to a lasting, disease-modifying treatment is restoring frataxin itself through gene therapy, protein replacement, or epigenetic approaches.

Gene therapy aims to treat Friedreich ataxia by giving cells a working FXN gene, but delivering just the right, safe amount of frataxin has been tricky. Using a viral vector carrying the human FXN gene, researchers treated mice and, 7 to 10 months later, measured frataxin in the heart and liver. The therapy produced human frataxin in a dose-dependent way, reaching levels comparable to the animals' own natural frataxin, and the protein was correctly processed into its mature form. The results support this vector as a promising route toward frataxin-restoring gene therapy.

MOXIe tested omaveloxolone, a capsule that activates Nrf2, a switch that turns on the cell's antioxidant defences, in people aged 16 to 40 with Friedreich's ataxia. The study ran in two parts across eleven sites in five countries: a dose-finding stage, then a placebo-controlled stage in 103 participants measured on the modified Friedreich's Ataxia Rating Scale (mFARS), the standard scale of neurological function in this disease.

What happenedPart 2 met its primary endpoint: after 48 weeks, mFARS scores improved by 1.55 points on omaveloxolone and worsened by 0.85 on placebo, a difference of 2.40 points (p=0.014). On that result the FDA approved omaveloxolone in February 2023 as Skyclarys, the first treatment ever approved for Friedreich's ataxia, followed by European approval in 2024. A long-term study following people taking it in ordinary clinical care is listed among the active trials above.

NICOFA was a planned European trial of nicotinamide, a form of vitamin B3, in Friedreich's ataxia. The rationale was solid: the FXN gene is not deleted in this condition but switched off, and an earlier proof-of-concept study in ten people had shown that nicotinamide could partly reverse that silencing and raise frataxin levels. Seven centers across six countries were to take part, with a placebo-controlled design.

What happenedThe trial never opened. After a temporary halt delayed the start of recruitment, the sponsor re-evaluated and concluded that the study was no longer feasible given the increased administrative and financial requirements, and it was formally withdrawn with no participants enrolled. It is listed here because a withdrawn trial is easy to mistake for an option that still exists, and because the underlying idea, reactivating the silenced FXN gene, is very much still being pursued by others.

MOVE-FA tested vatiquinone, an oral drug that blocks 15-lipoxygenase, an enzyme involved in the runaway oxidative damage seen in Friedreich's ataxia, in 146 children and young adults across fourteen sites in nine countries. Participants took the drug or placebo for 72 weeks, with change in mFARS score as the main measure. It was one of the largest pediatric-inclusive trials the condition has had.

What happenedThe trial did not meet its primary endpoint. mFARS worsened by 1.22 points on vatiquinone and 2.83 on placebo, a 1.61-point difference favoring the drug that fell short of statistical significance (p=0.14). Results on some individual components, particularly upright stability, looked stronger, and the sponsor has continued the program on that basis: a long-term efficacy study of vatiquinone appears among the trials preparing to open, listed above.

This phase 3 trial tested RT001, a chemically modified form of linoleic acid designed to resist the lipid peroxidation that damages cell membranes in Friedreich's ataxia. Sixty-five participants at six United States sites took the drug or placebo for eleven months. Unusually, the main measure was not a neurological rating scale but peak oxygen consumption during exercise testing, a physiological measure of how well the body's energy system is working.

What happenedThe trial completed in 2021 and missed its primary endpoint: the change in peak oxygen consumption was essentially the same on the drug and on placebo (p=0.59). The result is a useful piece of evidence about the choice of endpoint as much as about the drug, and exercise-based measures have largely given way to mFARS and to cardiac imaging in the trials that have followed.

STEADFAST tested interferon gamma-1b, an existing licensed medicine, in 92 children and adults with Friedreich's ataxia at four United States sites, on the strength of earlier work suggesting it could raise frataxin, the protein people with this condition cannot make enough of. Participants received the drug or placebo for 26 weeks, with the neurological section of the Friedreich's Ataxia Rating Scale as the main measure.

What happenedThe trial completed in late 2016 and found no benefit: scores changed by -0.6 points on interferon gamma-1b and -1.0 on placebo, with no significant difference (p=0.54). The sponsor discontinued development for Friedreich's ataxia, and the open-label extension that had been running alongside it was closed early as a direct consequence. It remains a clean example of a repurposing idea that did not survive a properly controlled test.

MICONOS was one of the pivotal European trials of idebenone, a synthetic relative of coenzyme Q10 taken as a tablet, in 232 people with Friedreich's ataxia across thirteen sites in six countries. Participants took one of several doses or placebo for a year, measured on the International Cooperative Ataxia Rating Scale. Idebenone had been the most widely used unapproved treatment in the condition for years, prescribed largely on the basis of small studies.

What happenedThe trial did not show a benefit on its primary neurological measure, and together with the parallel North American studies it ended idebenone's path to approval for Friedreich's ataxia; a marketing application was withdrawn in Europe. This is the trial most often cited when clinicians explain why idebenone is no longer recommended for the neurological features of the disease, and it is part of why the field shifted toward frataxin-targeted and antioxidant-pathway approaches.